Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use

Neuroscience

Volumn 87, Issue 1, 1998, Pages 63-78

  Court, J A ^a   Lloyd, S ^a   Thomas, N ^a   Piggott, M A ^a   Marshall, E F ^b   Morris, C M ^a   Lamb, H ^a   Perry, R H ^a   Johnson, M ^a   Perry, E K ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Apolipoprotein E; Dopamine receptors; Dopamine turnover; Human brain; Nicotinic receptors; Tobacco smoking

Indexed keywords

BUNGAROTOXIN; DOPAMINE RECEPTOR; HOMOVANILLIC ACID; NICOTINIC ACID; NICOTINIC RECEPTOR;

ARTICLE; AUTOPSY; BINDING AFFINITY; CHOLINERGIC TRANSMISSION; CIGARETTE SMOKING; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; ELDERLY CARE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RISK FACTOR; SMOKING HABIT; TOBACCO;

AGE FACTORS; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS E; BRAIN; BUNGAROTOXINS; CARRIER PROTEINS; CEREBELLUM; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HIPPOCAMPUS; HOMOVANILLIC ACID; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, NICOTINIC; SEX FACTORS; SMOKING;

EID: 0032581179     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00088-8     Document Type: Article

References (129)

1. Aldrich M. S., Hollingsworth Z., Penney J. B. Dopamine receptor autoradiography of human narcoleptic brain. Neurology. 42:1992;410-415.
2. Alexander G. M., Schwartzman R. J., Brainard L., Gordon S. W., Grothusen J. R. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res. 588:1992;261-269.
3. Aubert I., Araujo D. M., Cecyre D., Robitaille Y., Gauthier S., Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58:1992;529-541.
4. Baldessarini R. J. (1997) Dopamine receptors and clinical medicine. In The Dopamine Receptors (eds Neve K. A. and Neve R. L.), pp. 457-498. Humana, Totowa, New Jersey.
5. Balfour D. J. Neural mechanisms underlying nicotine dependence. Addiction. 89:1994;1419-1423.
6. Baron J. A. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br. med. Bull. 52:1996;58-73.
7. Barrantes G. E., Rogers A. T., Lindstrom J., Wonnacott S. α-Bungarotoxin binding sites in rat hippocampal and cortical cultures: initial characterisation, colocalisation with α7 subunits and up-regulation by chronic nicotine treatment. Brain Res. 672:1995;228-236.
8. Becker T., Elmer K., Schneider F., Schneider M., Grodd W., Bartels M., Heckers S., Beckmann H. Confirmation of reduced temporal limbic structure volume on magnetic resonance imaging in male patients with schizophrenia. Psychiat. Res. 67:1996;135-143.
9. Benwell M. E., Balfour D. J., Anderson J. M. Smoking-associated changes in the serotonergic systems of discrete regions of human brain. Psychopharmacology. 102:1990;68-72.
10. Benwell M. E. M., Balfour D. J. K. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br. J. Pharmac. 105:1992;849-856.
11. 3H]nicotine binding sites in human brain. J. Neurochem. 50:1988;1243-1247.
12. Benwell M. E. M., Balfour D. J. K., Khadra L. F. Studies on the influence of nicotine infusions on mesolimbic dopamine and locomotor responses to nicotine. Clin. Invest. 72:1994;233-239.
13. Bhat R. V., Marks M. J., Collins A. C. Effects of chronic nicotine infusion on kinetics of high-affinity nicotine binding. J. Neurochem. 62:1994;574-581.
14. Bhat R. V., Turner S. L., Marks M. J., Collins A. C. Selective changes in sensitivity to cholinergic agonists and receptor changes elicited by continuous physostigmine infusion. J. Pharmac. exp. Ther. 255:1990;187-196.
15. Bhat R. V., Turner S. L., Selvaag S. R., Marks M. J., Collins A. C. Regulation of brain nicotinic receptors by chronic agonist infusion. J. Neurochem. 56:1991;1932-1939.
16. 3H]nicotine binding in human postmortem brain. J. Pharmac. exp. Ther. 282:1997;7-13.
17. Carr L. A., Basham J. K. Effects of tobacco smoke constituents on MPTP-induced toxicity and monoamine oxidase activity in the mouse brain. Life Sci. 48:1991;1173-1177.
18. Clarke P. B. S. The fall and rise of neuronal α-bungarotoxin binding proteins. Trends pharmac. Sci. 13:1992;407-413.
19. 125I]-α-bungarotoxin. J. Neurosci. 5:1985;1307-1315.
20. Collins A. C., Bhat R. V., Pauly J. R., Marks M. J. Modulation of nicotine receptors by chronic exposure to nicotinic agonists and antagonists. Ciba Foundation Symposium. 152:1990;68-82.
21. Collins A. C., Romm E., Wehner J. M. Dissociation of the apparent relationship between nicotine tolerance and upregulation on nicotinic receptors. Brain Res. Bull. 25:1990;373-379.
22. Court J. A., Lloyd S., Johnson M., Griffiths M., Birdsall N. J. M., Piggott M. A., Oakley A. E., Ince P. G., Scott D. J., Perry E. K., Perry R. H. Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Devl Brain Res. 101:1997;93-105.
23. Court J. A., Perry E. K. CNS nicotinic receptors - possible therapeutic targets in neurodegenerative disorders. CNS Drugs. 2:1994;216-233.
24. Court J. A. and Perry E. K. (1995) Distribution of nicotinic receptors in the CNS. In CNS Neurotransmitters and Neuromodulators: Acetylcholine (ed. Stone T. W.), pp. 85-104. CRC, Boca Raton.
25. Court J. A., Perry E. K., Spurden D., Griffiths M., Kerwin J. M., Morris C. M., Johnson M., Oakley A. E., Birdsall N. J. M., Clementi F., Perry R. H. The role of the cholinergic system in the development of the human cerebellum. Devl Brain Res. 90:1995;159-167.
26. Court J. A., Perry E. K., Spurden D., Lloyd S., Gillespie J. I., Whiting P., Barlow R. Comparison of the binding of nicotinic agonists to receptors from human and rat cerebral cortex and from chick brain (α4β2) transfected into mouse fibroblasts with ion channel activity. Brain Res. 667:1994;118-122.
27. Court J. A., Piggott M. A., Perry E. K., Barlow R. B., Perry R. H. Age associated decline in high affinity nicotine binding in human brain frontal cortex does not correlate with the changes in choline acetyltransferase activity. Neurosci. Res. Commun. 10:1992;125-133.
28. Craviso G. L., Hemelt V. B., Waymire J. C. Nicotinic cholinergic regulation of tyrosine hydroxylase gene expression and catecholamine synthesis in isolated bovine adrenal chromaffin cells. J. Neurochem. 59:1992;2285-2296.
29. Cruz-Sanchez F. F., Cardozo A., Tolosa E. Neuronal changes in the substantia nigra with aging: a Golgi study. J. Neuropath. exp. Neurol. 54:1995;74-81.
30. Dalack G. W., Meador-Woodruff J. H. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schiz. Res. 22:1996;133-141.
31. Damsma G., Day J., Fibiger H. C. Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur. J. Pharmac. 168:1989;363-368.
32. Davies P., Feisullin S. Postmortem stability of α-bungarotoxin binding sites in mouse and human brain. Brain Res. 216:1981;449-454.
33. 3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology. 36:1997;779-786.
34. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. natn. Acad. Sci. U.S.A. 85:1988;5274-5278.
35. Elliott K. J., Ellis S. B., Berckhan K. J., Urrutia A., Chavez-Noriega L. E., Johnson E. C., Veliçelebi G., Harpold M. M. Comparative structure of human neuronal α2-α7 and β2-β4 nicotinic acetylcholine receptor subunits and functional expression of the α2, α3, α4, α7, β2 and β4 subunits. J. molec. Neurosci. 1996:1996;217-228.
36. Faraldi F., Reyes M. G., Alfieri E., Levi A. C. The aging substantia nigra: quantitative histologic study. Panminerva Medica. 36:1994;103-108.
37. Flores C. M., Dávila-García M., Ulrich Y. M., Kellar K. J. Differential regulation of neuronal receptor binding sites following chronic nicotine administration. J. Neurochem. 69:1997;2216-2219.
38. Flores C. M., Rogers S. W., Pabreza L. A., Wolfe B. B., Kellar K. J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4β2 subunits and is up-regulated by chronic nicotine treatment. Molec. Pharmac. 41:1992;31-37.
39. 3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. J. Neurochem. 47:1986;1948-1954.
40. Forno L. S. Neuropathology of Parkinson's disease. J. Neuropath. exp. Neurol. 55:1996;259-272.
41. Fowler J. S., Volkow N. D., Wang G.-J., Pappas N., Logan J., MacGregor R., Alexoff D., Shea C., Schlyer D., Wolf A. P., Warner D., Zezulkova I., Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 379:1996;733-736.
42. Freedman R., Hall M., Adler L. E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in Schizophrenia. Biol. Psychiat. 38:1995;22-33.
43. Gall C. M. Regulation of brain neurotrophin expression by physiological activity. Trends pharmac. Sci. 13:1992;401-403.
44. Gilbert D. G. Depression, smoking and nicotine: toward a bioinformational situation by trait model. Drug Dev. Res. 38:1996;267-277.
45. Glenthoj B. Y., Hemmingsen R. Dopaminergic sensitization: implications for the pathogenesis of schizophrenia. Prog. Neuropsych. biol. Psych. 21:1997;23-46.
46. Gopalakrishnan M., Molinari E. J., Sullivan J. P. Regulation of human α4β2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways. Molec. Pharmac. 52:1997;524-534.
47. 3H]dopamine release from mouse striatal synaptosomes. J. Neurochem. 62:1994;1390-1398.
48. 2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 602:1993;290-303.
49. Grenhoff J., Janson A. M., Svensson T. H., Fuxe K. Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the meso-diencephalic junction. Brain Res. 562:1991;347-351.
50. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 11:1994;245-256.
51. 3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res. 648:1994;222-228.
52. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv. Neurol. 60:1993;140-147.
53. Hsu Y.-N., Amin J., Weiss D. S., Wecker L. Sustained nicotine exposure differentially affects α3β2 and α4β2 neuronal nicotinic receptors expressed in Xenopus oocytes. J. Neurochem. 66:1996;667-675.
54. Hurd Y. L., Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse. 13:1993;357-369.
55. Ince P., Irving D., MacArthur F., Perry R. H. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly controls. J. neurol. Sci. 106:1991;142-152.
56. Janson A. M., Fuxe K., Agnati L. F., Bjelke B., Sundstrom E., Andersson K., Harfstand A., Goldstein M., Owman C. Protective effects of chronic nicotine treatment on lesioned dopamine neurons in the male rat. Prog. Brain Res. 79:1989;257-265.
57. 2 agonist binding in the rat basal ganglia. NeuroReport. 3:1992;1117-1120.
58. Janson A. M., Meana J. J., Goiny M., Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neurosci. Lett. 134:1991;88-92.
59. 2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse. 2:1988;546-557.
60. Kinnear P. R. and Gray D. G. (1994) SPSS for Windows made Simple. Psychology Press, Hove, U.K.
61. Kirch D. G., Gerhardt G. A., Shelton R. C., Freedman R., Wyatt R. J. Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clin. Neuropharmac. 10:1987;376-383.
62. 2 dopamine receptors. J. Pharm. Pharmac. 42:1992;89-92.
63. Kopin I. J. Catecholamine metabolism: basic aspects and clinical significance. Pharmac. Rev. 37:1985;333-364.
64. Lee P. N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology. 13:1994;131-144.
65. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. natn. Acad. Sci. U.S.A. 89:1992;8155-8159.
66. 3 receptors. Molec. Psychiat. 43:1993;749-754.
67. Marks M. J., Campbell S. M., Romm E., Collins A. C. Genotype influences the development of tolerance to nicotine in the mouse. J. Pharmac. exp. Ther. 259:1991;392-402.
68. Marks M. J., Grady S. R., Collins A. C. Downregulation of nicotinic receptor function after chronic nicotine infusion. J. Pharmac. exp. Ther. 266:1993;1268-1276.
69. Marks M. J., Pauly J. R., Gross S. D., Deneris E. S., Hermans-Borgmeyer I., Heineman S. F., Collins A. C. Nicotine binding and nicotinic receptor subunit mRNA after chronic nicotine treatment. J. Neurosci. 12:1992;2765-2784.
70. Marks M. J., Stitzel J. A., Collins A. C. Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J. Pharmac. exp. Ther. 235:1985;619-628.
71. Marshall D. L., Redfern P. H., Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem. 68:1997;1511-1519.
72. Marshall E. F., Perry E. K., Perry R. H., McKeith I. G., Fairbairn A. F., Thompson P. Dopamine metabolism in post-mortem caudate nucleus in neurodegenerative disorders. Neurosci. Res. Commun. 14:1994;17-25.
73. McEvoy J. P., Lindgren J. Smoking and schizophrenia. Drug Dev. Res. 38:1996;263-266.
74. McGehee D. S., Heath M. J. S., Gelber S., Devay P., Role L. W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
75. McGehee D. S., Role L. W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. A. Rev. Physiol. 57:1995;521-546.
76. Miner L. L., Collins A. C. Strain comparison of nicotine-induced seizure sensitivity and nicotinic receptors. Pharmac. Biochem. Behav. 33:1989;469-475.
77. Mizukawa K., Mcgeer E. G., McGeer P. L. Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their stria from patients with Parkinson disease, Alzheimer disease and neurologically normal controls. Molec. chem. Neuropath. 18:1993;133-144.
78. Morens D. M., Grandinetti A., Reed D., White L. R., Ross G. W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. 45:1995;1041-1051.
79. Morris C. M. M., Massey H. M., Benjamin R., Leake A., Broadbent C., Griffiths M., Lamb H., Brown A., Ince P. G., Tyrer S., Thompson P., McKeith I. G., Edwardson J. A., Perry R. H., Perry E. K. Molecular biology of Apo E alleles in Alzheimer's and non-Alzheimer's dementias. J. neural Transm. 47 (Suppl.):1996;205-218.
80. Mulle C., Choquet D., Korn H., Changeux J. P. Calcium influx through nicotinic receptor in rat central neurons: its relevance to cellular regulation. Neuron. 8:1992;135-143.
81. 2 receptors to mesostriatal regions of human forebrain. Proc. natn. Acad. Sci. U.S.A. 91:1994;11271-11275.
82. Nakayama H., Nakashima T., Kurogochi Y. α4 is a major acetylcholine binding subunit of cholinergic ligand affinity-purified nicotinic acetylcholine receptor from rat brains. Neurosci. Lett. 121:1991;122-124.
83. Nisell M., Nomikos G. G., Hertel P., Panagis G., Svensson T. H. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse. 22:1996;369-381.
84. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cereb. Brain Metab. Rev. 4:1992;303-328.
85. 11C]nicotine in human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology. 115:1994;31-36.
86. Nybäck H., Nordberg A., Långstöm B., Halldin C., Åhlin A., Swahn C. G., Sedvall G. Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography. Prog. Brain Res. 79:1989;313-319.
87. Olale F., Gerzanich V., Kuryatov A., Wang F., Lindstrom J. Chronic nicotine exposure differentially affects the funtion of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J. Pharmac. exp. Ther. 283:1997;675-683.
88. Pang Y., Kiba H., Jayaraman A. Acute nicotine injections induce c-fos mostly in non-dopaminergic neurons of the midbrain of the rat. Molec. Brain Res. 20:1993;162-170.
89. Pauly J. R., Marks M. J., Gross S. D., Collins A. C. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J. Pharmac. exp. Ther. 258:1991;1127-1136.
90. Perry E. K., Morris C. M., Court J. A., Cheng A., Fairbairn A. F., McKeith I. G., Irving D., Brown A., Perry R. H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: possible index of early neuropathology. Neuroscience. 64:1995;385-395.
91. Perry E. K., Smith C. J., Court J. A., Perry R. H. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. neural Transm. 2:1990;149-158.
92. Pich E. M., Pagliusi S. R., Tessari M., Talabot-Ayer D., Hooft van Huijsduijnen R., Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 275:1997;83-86.
93. Pietila K., Salminen O., Leikola-Pelho T., Ahtee L. Tolerance to nicotine's effects on striatal dopamine metabolism in nicotine-withdrawn mice. Eur. J. Pharmac. 318:1996;17-22.
94. Piggott M. A., Court J. A., Perry E. K., Lloyd S., Thomas N. J., Smith Z. M., Johnson M., Perry R. H., McKeith I. G. Dopaminergic and nicotinic interactions in the human striatum in dementia with Lewy bodies, chronic schizophrenia and Parkinson's disease. Eur. Neuropsychopharmac. 6(S4):1996;103.
95. Piggott M. A. and Marshall E. F. (1996) Neurochemical correlates of extra-pyramidal symptoms. In Dementia with Lewy Bodies - Clinical, Pathological and Treatment Issues (eds Perry R. H., McKeith I. G. and Perry E. K.), pp. 449-467. Cambridge University Press, Cambridge.
96. Playford E. D., Brooks D. J. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cereb. Brain Metab. Rev. 4:1992;144-171.
97. Poirier J., Delisle M., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrandt P., Nalbantoglu J., Gilfix B., Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. natn. Acad. Sci. U.S.A. 92:1995;12260-12264.
98. Prasad C., Ikegami H., Shimizu I., Onaivi E. S. Chronic nicotine intake decelerates aging of nigrostriatal dopaminergic neurons. Life Sci. 54:1994;1169-1184.
99. 2 dopamine receptors. J. Neurochem. 62:1994;411-420.
100. Rasmussen K., Czachura J. F. Nicotine withdrawal leads to increased firing rates of midbrain dopamine neurons. NeuroReport. 7:1995;329-332.
101. 3H]domperidone in rat nucleus accumbens. J. Neurosci. Res. 18:1987;621-625.
102. Ren T., Sagar S. M. Induction of c-fos immunostaining in the rat brain after the systemic administration of nicotine. Brain Res. Bull. 29:1992;589-597.
103. 11C]raclopride. J. cerebr. Blood Flow Metab. 13:1993;310-314.
104. Rogers A. T., Wonnacott S. Nicotine-induced upregulation of alpha bungarotoxin binding sites in cultured rat hippocampal neurons. Biochem. Soc. Trans. 23:1995;48S.
105. Role L. W. Diversity in primary structure and function of neuronal nicotinic acetylcholine receptor chanels. Curr. Opin. Neurobiol. 2:1992;254-262.
106. Rowell P. P., Hillebrand J. A. Characterization of nicotine-induced densensitization of evoked dopamine release from rat striatal synaptosomes. J. Neurochem. 63:1994;561-569.
107. Rowell P. P., Wonnacott S. Evidence for functional activity of up-regulated nicotine binding sites in rat striatal synaptosomes. J. Neurochem. 55:1990;2105-2110.
108. Rubboli F., Court J. A., Sala C., Morris C., Chini B., Perry E., Clementi F. Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur. J. Neurosci. 6:1994;1596-1604.
109. 2 receptors varies along the rostrocaudal axis of the hippocampal complex in Alzheimer's disease. J. comp. Neurol. 348:1994;94-110.
110. Sanderson E. M., Drasdo A. L., McCrea K., Wonnacott S. Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res. 617:1993;349-352.
111. Sargent P. B. The diversity of neuronal nicotinic acetylcholine receptors. A. Rev. Physiol. 16:1993;403-443.
112. Schoepfer R., Whiting P., Esch F., Blacher R., Shimasaki S., Lindstrom J. cDNA clones coding for the structural subunit of a chicken brain acetylcholine receptor. Neuron. 1:1988;241-248.
113. 3 receptor: basic and clinical aspects. Clin. Neuropharmac. 16:1993;295-314.
114. Sershen H., Hashim A., Wiener H. L., Lajtha A. Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse. Neurosci. Lett. 93:1988;270-274.
115. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. 16:1996;6100-6106.
116. Sugaya K., Giacobini E., Chiappinelli V. A. Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J. Neurosci. Res. 27:1990;349-359.
117. Tomlinson B. E., Blessed G., Roth M. Observations on the brains of non-demented old people. J. neurol. Sci. 7:1968;331-356.
118. Tompkins M. M., Basgall E. J., Zamrini E., Hill W. D. Apoptotic-like changes in Lewy body-associated disorders and normal aging in substantia nigral neurons. Am. J. Path. 150:1997;119-131.
119. Trouslard J., Marsh S. J., Brown J. A. Calcium entry through nicotinic receptor channels and calcium channels in cultured superior cervical ganglion cells. J. Physiol. 468:1993;53-71.
120. Vernino S., Amador M., Luetje C. W., Patrick J., Dani J. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron. 8:1992;127-134.
121. Vizi E. S., Sershen H., Balla A., Mike Á., Windisch K., Jurányi Z. S., Lajtha A. Neurochemical evidence of heterogeneity of presynaptic and somatodendritic nicotinic acetylcholine receptors. Ann. N. Y. Acad. Sci. 757:1995;84-99.
122. Westfall T. C., Mereu G., Vickery L., Perry H., Naes L., Yoon K. W. Regulation by nicotine of midbrain dopamine neurons. Prog. Brain Res. 79:1989;173-185.
123. Wevers A., Jeske A., Lobron C., Birtsch C., Heinemann S., Maelicke A., Schöder R., Schröder H. Cellular distribution of nicotinic acetylcholine receptor subunit mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization. Molec. Brain Res. 25:1994;122-128.
124. Whiting P., Lindstrom J. Purification and characterization of a nicotinic acetylcholine receptor from rat brain. Proc. natn. Acad. Sci. U.S.A. 84:1987;595-599.
125. Whiting P. J., Esch F., Shimasaki S., Lindstrom J. Neuronal nicotinic acetylcholine receptor subunit is coded by the cDNA α4. Fedn Eur. biochem. Socs Lett. 219:1987;459-463.
126. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20:1997;92-98.
127. Yates S. L., Bencherif M., Fluhler E. N., Lippiello P. M. Up-regulation of nicotinic acetylcholine receptors following chronic exposure of rats to mainstream cigarette smoke or α4β2 receptors to nicotine. Biochem. Pharmac. 50:1995;2001-2008.
128. Yu J. Z., Wecker L. Chronic nicotine administration differentially affects neurotransmitter release from rat striatal slices. J. Neurochem. 63:1994;186-194.
129. Zaidel D. W., Esiri M. M., Harrison P. J. Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. Am. J. Psychiat. 154:1997;812-818.